Core Insights - The company reported third-quarter revenue of 156 million, representing a year-over-year increase of 66.31% [1] - The net profit for the third quarter was 5.31 million, showing a year-over-year growth of 132.74% [1] - For the first three quarters, the company achieved a revenue of 422 million, which is a 46.47% increase compared to the same period last year [1] - The net profit for the first three quarters reached 10.32 million, reflecting a year-over-year growth of 132.00% [1]

Company Overview - Meixinsheng Technology (Beijing) Co., Ltd. is located in Haidian District, Beijing, and was established on March 11, 2008. The company specializes in the research and sales of high-performance analog and mixed-signal chips in integrated circuit design [1]. Stock Performance - On October 14, Meixinsheng's stock fell by 5.03%, trading at 44.53 CNY per share, with a transaction volume of 150 million CNY and a turnover rate of 3.81%. The total market capitalization is 4.967 billion CNY [1]. Fund Holdings - According to data from the top ten holdings of funds, one fund under Chuangjin Hexin holds a significant position in Meixinsheng. The Chuangjin Hexin Innovation-Driven Stock A Fund (010495) held 83,500 shares in the second quarter, accounting for 4.79% of the fund's net value, making it the largest holding [2]. - The Chuangjin Hexin Innovation-Driven Stock A Fund was established on December 30, 2020, with a latest scale of 62.875 million CNY. Year-to-date, it has achieved a return of 40.73%, ranking 1073 out of 4220 in its category. Over the past year, it has returned 35.07%, ranking 1623 out of 3857 [2]. - The fund manager, Guo Zhenyue, has been in position for 145 days, with the fund's total asset scale at 82.1407 million CNY. During his tenure, the best fund return was 53.6%, while the worst was 53.14% [2].

美芯晟科技（北京）股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688458 证券简称：美芯晟 公告编号：2025-051 截至2025年9月30日，公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份 1,393,700股，占公司总股本111,536,629股的比例为1.2495%，回购成交的最高价为41.525元/股，最低价 为30.12元/股，成交总金额为人民币49,954,672.12元（不含印花税、交易佣金等交易费用）。 上述股份回购符合法律法规的规定及公司回购股份方案的要求。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股 份》等相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进 展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 ■ 一、回购股份的基本情况 ...

格隆汇10月9日丨美芯晟(688458.SH)公布，截至2025年9月30日，公司通过上海证券交易所交易系统以 集中竞价交易方式累计回购公司股份139.37万股，占公司总股本的比例为1.2495%，回购成交的最高价 为41.525元/股，最低价为30.12元/股，成交总金额为人民币4995.47万元（不含印花税、交易佣金等交易 费用）。 ...

Core Viewpoint - Meixinsheng (688458.SH) announced a share buyback program, indicating a commitment to returning value to shareholders and potentially signaling confidence in the company's future performance [1] Summary by Categories Share Buyback Details - The company has repurchased a total of 1.3937 million shares, which represents 1.2495% of the total share capital [1] - The highest price for the repurchased shares was 41.525 CNY per share, while the lowest price was 30.12 CNY per share [1] - The total amount spent on the share buyback was approximately 49.9547 million CNY, excluding transaction fees such as stamp duty and commissions [1]

美芯晟科技（北京）股份有限公司 | 回购方案首次披露日 | 2025/1/18 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 月 16 1 | 1 | 日~2026 | 年 | 月 | 15 日 | | 预计回购金额 | 2,500万元~5,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 1,393,700股 | | | | | | | 累计已回购股数占总股本比例 | 1.2495% | | | | | | | 累计已回购金额 | 4,995.47万元 | | | | | | | 实际回购价格区间 | 30.12元/股~41.525元/股 | | | | | | 一、回购股份的基本情况 关于以集中竞价交易方式回购公司股份的进展公告 证券代码：688458 证券简称：美芯晟 公告编号：2025-051 本公司董事会及全体董事保证 ...

Core Viewpoint - The announcement from Meixinsheng indicates that shareholder WI HARPER FUND VII HONG KONG LIMITED plans to reduce its stake in the company by up to 1% through market transactions between October 29, 2025, and January 28, 2026, primarily due to personal funding needs [1][3]. Group 1 - The planned reduction involves selling up to 1,115,366 shares, which represents a decrease from 5.59% to approximately 4.59% of the total share capital [1][3]. - The reduction will be executed at market prices, and the company emphasizes compliance with relevant laws and regulations, ensuring no substantial impact on governance or future strategic development [3]. - Industry analysts suggest that institutional shareholder reductions often stem from investment cycles and personal funding arrangements, rather than a negative outlook on the company's fundamentals [3]. Group 2 - Meixinsheng has been consistently investing in research and development in the simulation chip sector, maintaining a competitive market position [3]. - The company aims to focus on its core business development, enhancing operational performance through technological innovation and market expansion to create long-term stable value for shareholders [3].

Core Viewpoint - Several companies are planning to reduce their shareholdings, indicating potential shifts in ownership and investor sentiment in the market [1] Shareholder Reductions - Senba Sensor's actual controller's concerted action party plans to reduce holdings by no more than 1.09% [1] - Erkang Pharmaceutical's controlling shareholder intends to reduce holdings by no more than 2.04% [1] - Andeli's shareholder BVI Donghua plans to reduce holdings by no more than 1.00% [1] - Zhiyang Innovation's controlling shareholder and its concerted action party plan to reduce a total of no more than 4.225 million shares [1] - Sichuan Gold's shareholder Beijing Jinyang intends to reduce holdings by no more than 1.8% [1] - Guoji Heavy Industry's shareholders, including Bank of China Deyang Branch and Bank of China Zhenjiang Runzhou Branch, plan to reduce a total of no more than 1% [1] - Meixin Sheng's shareholder WI Harper Fund VII plans to reduce holdings by no more than 1% [1] - Yanmian Technology's actual controller and controlling shareholder Liu Yan plan to reduce a total of 1.2897% of the company's shares [1] - Jingwei Henghai's supervisor Cui Wenge plans to reduce no more than 600,000 shares [1] - New Xiangwei's shareholder Kehongxin plans to reduce holdings by no more than 1% [1] - Wujin Stainless Steel's three executives plan to reduce a total of no more than 623,400 shares [1] - Zhongrun Optical's director Lu Gaofei plans to reduce no more than 695,300 shares [1] Regulatory Actions - *ST Mubang's actual controller Liao Zhiyuan has received a notice of investigation from the China Securities Regulatory Commission [1] - Youkeshu's shareholder has also received a notice of investigation from the China Securities Regulatory Commission [1]

Group 1 - Yinglian Co., Ltd. expects a net profit of 34.5 million to 37.5 million yuan for the first three quarters of 2025, representing a year-on-year increase of 1531% to 1673% [1] - China CNR Corporation signed major contracts totaling approximately 54.34 billion yuan, accounting for 22% of its expected revenue for 2024 [1] - Shengmei Shanghai reported a total order amount of 9.072 billion yuan, a year-on-year increase of 34.1% [2] Group 2 - Fulian Precision plans to increase capital in its subsidiary Jiangxi Shenghua with a total investment of 35.63 billion yuan, which is expected to constitute a major asset restructuring [3] - Aimeike has obtained a drug registration certificate for Minoxidil topical solution, which is used for treating male pattern baldness [4] - Guolin Technology is planning to acquire 91.07% of Kailianjie’s equity for cash, which is expected to constitute a major asset restructuring [5] Group 3 - Baicheng Co. plans to purchase 55% of Shanghai Canxi Engineering Equipment Co. and will suspend trading of its stock starting September 30, 2025 [6][7] - Diaowei is planning to acquire equity in Rongpai Semiconductor and has suspended trading of its stock [8] - Xiatun New Energy signed a strategic cooperation framework agreement with Zhongwei Co. to establish a long-term partnership in the supply chain for solid-state lithium battery materials [9] Group 4 - Lingyi Zhi Manufacturing is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy [10] - Baicheng Pharmaceutical received clinical trial approval for its innovative drug BIOS-0623-Z4, which targets cancer pain treatment [11] - Weide Information announced a preliminary transfer price of 40.33 yuan per share, representing a 26% discount to its closing price [12] Group 5 - Huayou Cobalt's subsidiary signed contracts with LGES for the supply of 76,000 tons of ternary precursor materials and 88,000 tons of ternary cathode materials from 2026 to 2030 [13] - Hubei Energy signed a cooperation agreement with the Xiangyang Municipal Government to invest 26.7 billion yuan in clean energy projects [14]

Group 1 - Yinglian Co., Ltd. expects a net profit increase of 1531.13% to 1672.97% year-on-year for the first three quarters of 2025, with projected revenue of 1.63 billion to 1.65 billion yuan, a growth of 9.49% to 10.83% [1] - Meixin Sheng plans to reduce its shareholding by no more than 1% through centralized bidding and block trading [1] - Huayin Technology signed two sales contracts totaling 402 million yuan, with one contract for special functional materials and another for research project materials [3] Group 2 - Shen Highways reported a total toll revenue of 114 million yuan for August [5] - Dash Smart signed a contract worth 113 million yuan for a smart hospital project [7] - Tianbang Food received an administrative regulatory measure decision from the China Securities Regulatory Commission for failing to disclose information in a timely manner [8] Group 3 - Fashilong plans to invest 250 million yuan to establish a wholly-owned subsidiary focused on AI applications and cloud computing [10] - Junpu Intelligent received a government subsidy of 20 million yuan, accounting for 243.97% of its audited net profit for 2024 [11] - Longyun Co. plans to apply for a bank credit limit of 32 million yuan [12] Group 4 - Yifan Pharmaceutical's subsidiary received acceptance for a drug registration application for a medication used to lower phenylalanine levels in patients [12] - Rundu Co. received a drug registration certificate for a hypertension medication [13] - Huahai Qingke elected a new employee director and appointed a new vice president [17] Group 5 - Wanyi Technology received a government subsidy of 173,000 yuan [19] - Haizheng Pharmaceutical's tacrolimus capsules passed the consistency evaluation for generic drugs [20] - Pulaike's new veterinary vaccine received registration certification [22] Group 6 - Boguang New Materials signed a major sales contract estimated at 4.3 billion to 5 billion yuan for nickel powder products [41] - Electric Soul Network announced plans for shareholders to reduce their holdings by up to 1.63% [42] - Jin Haitong's shareholders plan to reduce their holdings by up to 3% [44]